OncoMatch/Clinical Trials/NCT05400603
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
Is NCT05400603 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate for neuroblastoma.
Treatment: Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate — The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate in children with refractory or recurrent neuroblastoma or refractory/ relapsed osteosarcoma as well as to define the toxicities of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Osteosarcoma
Prior therapy
Cannot have received: T cell therapy
Prior T cell therapy is excluded
Cannot have received: allogeneic stem cell transplant
Patients with prior allogeneic stem cell transplant
Lab requirements
Blood counts
Absolute Neutrophil count ≥750/uL and platelet count ≥ 75,000/µl, transfusion independent
Kidney function
age-adjusted serum creatinine ≤1.5 ULN for age
Liver function
Total bilirubin ≤ 1.5 x ULN for age and serum glutamic-pyruvic transaminase (SGPT) (ALT) ≤ 135 U/L (≤ 3x ULN)
Cardiac function
Normal ejection fraction (≥ 55%) documented by either echocardiogram or radionuclide multigated acquisition scan (MUGA) evaluation OR Normal fractional shortening (≥ 27%) documented by echocardiogram
Hematologic Functions : Absolute Neutrofil count ≥750/uL and platelet count ≥ 75,000/µl, transfusion independent. Renal Function: Patients must have adequate renal function defined as age-adjusted serum creatinine ≤1.5 ULN for age. Liver Function: Total bilirubin ≤ 1.5 x ULN for age and serum glutamic-pyruvic transaminase (SGPT) (ALT) ≤ 135 U/L (≤ 3x ULN). Cardiac Function: Normal ejection fraction (≥ 55%) documented by either echocardiogram or radionuclide multigated acquisition scan (MUGA) evaluation OR Normal fractional shortening (≥ 27%) documented by echocardiogram. Pulmonary Function: Normal pulmonary function with no evidence of dyspnea at rest, no exercise intolerance.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Healthcare of Atlanta · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify